CN110051843A - 预防或治疗左心室重塑的方法 - Google Patents

预防或治疗左心室重塑的方法 Download PDF

Info

Publication number
CN110051843A
CN110051843A CN201811549998.5A CN201811549998A CN110051843A CN 110051843 A CN110051843 A CN 110051843A CN 201811549998 A CN201811549998 A CN 201811549998A CN 110051843 A CN110051843 A CN 110051843A
Authority
CN
China
Prior art keywords
arg
lys
phe
dmt
aromatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811549998.5A
Other languages
English (en)
Chinese (zh)
Inventor
D·特拉维斯·威尔逊
罗伯特·A·科鲁纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stealth Peptides International Inc
Original Assignee
Stealth Peptides International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Peptides International Inc filed Critical Stealth Peptides International Inc
Publication of CN110051843A publication Critical patent/CN110051843A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201811549998.5A 2013-05-14 2013-10-22 预防或治疗左心室重塑的方法 Pending CN110051843A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361823305P 2013-05-14 2013-05-14
US61/823,305 2013-05-14
CN201380078124.5A CN105579054A (zh) 2013-05-14 2013-10-22 预防或治疗左心室重塑的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380078124.5A Division CN105579054A (zh) 2013-05-14 2013-10-22 预防或治疗左心室重塑的方法

Publications (1)

Publication Number Publication Date
CN110051843A true CN110051843A (zh) 2019-07-26

Family

ID=51898747

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811549998.5A Pending CN110051843A (zh) 2013-05-14 2013-10-22 预防或治疗左心室重塑的方法
CN201380078124.5A Pending CN105579054A (zh) 2013-05-14 2013-10-22 预防或治疗左心室重塑的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380078124.5A Pending CN105579054A (zh) 2013-05-14 2013-10-22 预防或治疗左心室重塑的方法

Country Status (5)

Country Link
US (4) US20160256514A1 (cg-RX-API-DMAC7.html)
EP (2) EP3586864A1 (cg-RX-API-DMAC7.html)
JP (2) JP2016522196A (cg-RX-API-DMAC7.html)
CN (2) CN110051843A (cg-RX-API-DMAC7.html)
WO (1) WO2014185952A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3586864A1 (en) * 2013-05-14 2020-01-01 Stealth Biotherapeutics Corp Methods for the prevention or treatment of left ventricle remodeling
US20180318381A1 (en) * 2015-10-23 2018-11-08 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Methods of Treatment of Rhabdomyolysis
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
CN108042525B (zh) * 2017-12-20 2020-09-01 岳红 一种治疗心肌梗死后心室重塑的药物组合物
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
GB202000945D0 (en) * 2020-01-22 2020-03-04 Univ Oslo Treatment of cardiac remodelling
EP4168425A4 (en) * 2020-06-17 2024-06-19 Stealth BioTherapeutics Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULAR DYSTROPHY

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110082084A1 (en) * 2009-10-05 2011-04-07 Szeto Hazel H Methods for the prevention or treatment of heart failure
WO2011116007A1 (en) * 2010-03-15 2011-09-22 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
EP3725324A1 (en) * 2005-09-16 2020-10-21 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method for reducing cd36 expression
EP2519249A4 (en) * 2009-12-31 2013-06-26 Stealth Peptides Int Inc METHOD FOR CARRYING OUT A CORONARY ARTERY BYPASS PROCEDURE
US20130195837A1 (en) * 2009-12-31 2013-08-01 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
CN103249423A (zh) * 2010-07-09 2013-08-14 康肽德生物医药技术有限公司 预防或治疗缺血/再灌注损伤之后无复流的方法
WO2012115987A2 (en) * 2011-02-21 2012-08-30 The Trustees Of Columbia University In The City Of New York Methods for Treating and Preventing Cardiac Dysfunction in Septic Shock
CN107496899A (zh) * 2011-09-29 2017-12-22 梅约医学教育与研究基金会 芳族阳离子肽和使用它们的方法
EP3586864A1 (en) * 2013-05-14 2020-01-01 Stealth Biotherapeutics Corp Methods for the prevention or treatment of left ventricle remodeling

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110082084A1 (en) * 2009-10-05 2011-04-07 Szeto Hazel H Methods for the prevention or treatment of heart failure
WO2011116007A1 (en) * 2010-03-15 2011-09-22 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SIHAG S.,ET AL.: ""PGC-1alpha and ERRalpha target gene downregulation is a signature of the failing human heart"", 《JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY》 *

Also Published As

Publication number Publication date
JP2016522196A (ja) 2016-07-28
JP2019052157A (ja) 2019-04-04
CA2912386A1 (en) 2014-11-20
EP2996707A1 (en) 2016-03-23
HK1222794A1 (en) 2017-07-14
WO2014185952A1 (en) 2014-11-20
EP2996707A4 (en) 2016-12-07
US20250319152A1 (en) 2025-10-16
US20190358286A1 (en) 2019-11-28
EP2996707B1 (en) 2019-09-11
US20220296671A1 (en) 2022-09-22
US20160256514A1 (en) 2016-09-08
EP3586864A1 (en) 2020-01-01
CN105579054A (zh) 2016-05-11

Similar Documents

Publication Publication Date Title
US20230285499A1 (en) Methods for the prevention or treatment of heart failure
US20250319152A1 (en) Methods for the prevention or treatment of left ventricle remodeling
JP7381652B2 (ja) バース症候群の予防または治療のための方法及び組成物
US11266709B2 (en) Methods for the regulation of matrix metalloproteinase expression
US20200113966A1 (en) Methods and compositions for regulating srca2a expression levels in myocardial infarction
CA2912386C (en) Methods for the prevention or treatment of left ventricular remodeling
HK1222794B (en) Methods for the prevention or treatment of left ventricle remodeling
HK1233532A1 (en) Methods for the prevention or treatment of cardiac fibrosis
HK1176561A (en) Methods for the prevention or treatment of heart failure

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190726